Evidence map›Paper›PMID 36608652›Full record

ReviewCell2023

Phage therapy: From biological mechanisms to future directions.

Steffanie A Strathdee, Graham F Hatfull, Vivek K Mutalik, Robert T Schooley

Abstract readReview
In one paragraph

Review in Cell, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 483 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
483citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

483 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Analysis of bacteriophage diversity in Ganga river ecosystem: insights from metagenome-based sequencing.International microbiology : the official journal of the Spanish Society for Microbiology · 2026
    Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Review
  13. Article
  14. Review
  15. Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

423 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Steffanie A StrathdeeCenter for Innovative Phage Applications and Therapeutics, Division of Infectious Disease and Global Public Health, University of California, San Diego, La Jolla, CA 92093-0507, USA. Electronic address: sstrathdee@health.ucsd.edu.
Graham F HatfullDepartment of Biological Sciences, University of Pittsburgh, Pittsburgh, PA 15260, USA.
Vivek K MutalikEnvironmental Genomics and Systems Biology Division, Lawrence Berkeley National Laboratory, Berkeley, CA 94720, USA.
Robert T SchooleyCenter for Innovative Phage Applications and Therapeutics, Division of Infectious Disease and Global Public Health, University of California, San Diego, La Jolla, CA 92093-0507, USA.

Funding

Antibacterial Resistance Leadership Group (ARLG)UM1AI104681 · NIAID · DUKE UNIVERSITY · PI Vance G. Fowler, Henry F HENRY CHAMBERS · 2013 to 2026
$180.8M
Bacteriophage diversity, dynamics, function, and exploitationR35GM131729 · NIGMS · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI Graham F. Hatfull · 2019 to 2026
$3.6M
Deposition of 0.5 to 2 Micron Aerosol in the Human LungR01ES011184 · NIEHS · UNIVERSITY OF CALIFORNIA SAN DIEGO · PI PRISK, GORDON KIM · 2002 to 2003
$630k
NIAID NIH HHS UM1 AI104681NIEHS NIH HHS R01 ES011184NIGMS NIH HHS R35 GM131729
6 · The paper itself

Abstract

Increasing antimicrobial resistance rates have revitalized bacteriophage (phage) research, the natural predators of bacteria discovered over 100 years ago. In order to use phages therapeutically, they should (1) preferably be lytic, (2) kill the bacterial host efficiently, and (3) be fully characterized to exclude side effects. Developing therapeutic phages takes a coordinated effort of multiple stakeholders. Herein, we review the state of the art in phage therapy, covering biological mechanisms, clinical applications, remaining challenges, and future directions involving naturally occurring and genetically modified or synthetic phages.

Indexed as

BacteriophagesPhage TherapyBacteriabacteriophagebacteriophage therapyphagephage therapy

Identifiers

PMID36608652
PMCPMC9827498

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.